海翔药业：地夸磷索钠化学原料药获上市批准

Core Viewpoint - The company has received approval from the National Medical Products Administration for the marketing application of Diquafosol Sodium, a P2Y2 receptor agonist used in eye drops for the treatment of dry eye disease [1] Group 1: Company Information - The approved product, Diquafosol Sodium, is specifically formulated as an eye drop solution [1] - The company anticipates that the sales revenue for Diquafosol Sodium eye drops in urban public hospitals in China will reach RMB 131 million in 2024 [1] Group 2: Industry Context - Diquafosol Sodium is positioned within the therapeutic area of dry eye disease, which is a significant market in ophthalmology [1]